US Patent 11229633 Arimoclomol formulation
Patent 11229633 was granted and assigned to Orphazyme on January, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Article (+303 characters)
Article
Patent abstract
The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.
Edits on 15 Oct, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Anders Mørkeberg Hinsby0
Carlos Roberto Camozzi0
Gert Mads Bolwig0
Thomas Kirkegaard Jensen0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 27 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11229633 Arimoclomol formulation
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11229633
Date of patent
January 25, 2022
Patent application number
16826733
Date Filed
March 23, 2020
Patent primary examiner
Find more entities like US Patent 11229633 Arimoclomol formulation
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.